SAS and Carolina partner to accelerate antiviral drug development
Posted Nov 19, 2021
SAS, a leader in analytics and software services, and the University of North Carolina are teaming up to transform the drug development process to prevent infectious disease threats from turning into a pandemic like COVID-19. The partnership is focused on the work of the University’s Rapidly Emerging Antiviral Drug Development Initiative (READDI).
(UNC.edu)
Related: Campus Connections
UNC Alumni Premiere Their Movie Musical, Dreaming of an OscarThree years ago, a team of University of North Carolina students set out on a mission to win an Oscar. By creating an original movie...
Wed Dec 1, 2021Carolina Insider Podcast: Basketball's Big Week, Football Recap, Robbie BachFootball's regular season came to a stunning end in Raleigh. The Tar Heels now look to a bowl game (3:18). UNC Basketball faces an important...
Tue Nov 30, 2021Alumnus Kimathi Muiruri becomes Carolina’s 54th Rhodes ScholarUNC-Chapel Hill alumnus Kimathi Muiruri has received the prestigious Rhodes Scholarship, making him the 54th Tar Heel to be named a Rhodes Scholar. Muiruri, a...
Mon Nov 29, 2021UNC selected for esteemed national Innovation Corps programThe University of North Carolina at Chapel Hill has been selected as a National Science Foundation Innovation Corps site, part of a larger effort to...
Sun Nov 28, 2021
